Top-Rated StocksTop-RatedNASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $103.15 -1.08 (-1.04%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$103.16 +0.00 (+0.00%) As of 08/29/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$101.76▼$104.6250-Day Range$61.44▼$104.2352-Week Range$45.00▼$104.93Volume402,638 shsAverage Volume585,235 shsMarket Capitalization$6.85 billionP/E RatioN/ADividend YieldN/APrice Target$101.57Consensus RatingBuy Company Overview Rhythm Pharmaceuticals, Inc. is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation. The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1. Rhythm has advanced multiple Phase 3 clinical trials for setmelanotide and is pursuing regulatory approvals in both the United States and the European Union. In addition to its lead program, the company is exploring opportunities in related rare obesity indications and branching into other metabolic disorders tied to melanocortin pathway dysfunction. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals is led by a management team with extensive experience in drug development, regulatory strategy and commercialization of therapies for rare diseases. The company maintains a robust intellectual property portfolio around its peptide technology and collaborates with academic institutions and patient advocacy groups to advance understanding of rare genetic forms of obesity. Rhythm’s work underscores a commitment to precision medicine approaches that address the root causes of metabolic disorders.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 287th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.23% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 5.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.80 Percentage of Shares Shorted7.23% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 5.85%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.23 News SentimentRhythm Pharmaceuticals has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Rhythm Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,977,553.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Stock News HeadlinesInsider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 4,188 Shares of StockAugust 26, 2025 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 3,984 SharesAugust 14, 2025 | insidertrades.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 31 at 2:00 AM | Timothy Sykes (Ad)FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM)August 29 at 2:25 AM | finance.yahoo.comBrokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $101.57August 29 at 2:19 AM | americanbankingnews.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Insider Joseph Shulman Sells 4,188 SharesAugust 26, 2025 | americanbankingnews.comFDA Priority Review for Setmelanotide in Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM)August 21, 2025 | finance.yahoo.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $55.98 at the start of the year. Since then, RYTM shares have increased by 84.3% and is now trading at $103.15. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced its earnings results on Tuesday, August, 5th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.09. The firm's quarterly revenue was up 66.8% on a year-over-year basis. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Top institutional shareholders of Rhythm Pharmaceuticals include Primecap Management Co. CA (7.34%), Perceptive Advisors LLC (3.64%), State Street Corp (2.87%) and Federated Hermes Inc. (2.54%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, William T Roberts, Jennifer Kayden Lee, Jennifer Chien, Alastair Garfield, Lynn A Tetrault, Jennifer L Good and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/05/2025Today8/31/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Price Target for Rhythm Pharmaceuticals$101.57 High Price Target$135.00 Low Price Target$65.00 Potential Upside/Downside-1.5%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$260.60 million Net Margins-117.13% Pretax Margin-117.17% Return on Equity-1,831.43% Return on Assets-48.33% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.64 Sales & Book Value Annual Sales$130.13 million Price / Sales52.65 Cash FlowN/A Price / Cash FlowN/A Book Value($0.18) per share Price / Book-573.06Miscellaneous Outstanding Shares66,420,000Free Float62,368,000Market Cap$6.85 billion OptionableOptionable Beta2.38 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RYTM) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.